Yazar "Binay, Umut Devrim" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    The Impact of Vaccination Among Hospitalized Patients with the Diagnosis of COVID-19
    (Doc Design Informatics Co Ltd, 2023) Yildiz, Yesim; Ozger, Hasan Selcuk; Acar, Ali; Seremet-Keskin, Aysegul; Binay, Umut Devrim; Unlu, Gulten; Bayram, Halim
    Objective: We aimed to investigate the vaccination status and the risk factors for the intensive care unit (ICU) support need of the laboratory-confirmed breakthrough COVID-19 infection inpatients. Materials and Methods: This multi-center point-prevalence study was conducted on inpatients, divided into two groups as 'fully' and 'partially' vaccinated according to COVID-19 vaccination status. Results: Totally 516 patients were included in the study. The median age was 65 (55-77), and 53.5% (n=276) of the patients were male. Hypertension (41.9%, n=216), diabetes mellitus (DM) (31.8%, n=164), and coronary artery disease (CAD) (16.3%, n=84) were the predominant comorbidities. Patients were divided into two groups ICU (n=196) and non-ICU (n=301). Hypertension (p=0.026), DM (p=0.048), and congestive heart failure (CHF) (p=0.005) were significantly higher in ICU patients and the median age was younger among non-ICU patients (p=0.033). Of patients, 16.9% (n=87) were fully vaccinated, and this group's need for ICU support was statistically significantly lower (p=0.021). Conclusion: We conclude that older age, hypertension, DM, CHF, and being partially vaccinated were associated with the need for ICU support. Therefore, all countries should continuously monitor post-vaccination breakthrough COVID-19 infections to determine the national booster vaccine administration approach that will provide vulnerable individuals the highest protection.
  • Küçük Resim
    Öğe
    Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
    (AVES, 2020) Aygen, Bilgehan; Demirtürk, Neşe; Yıldız, Orhan; Çelen, Mustafa Kemal; Çelik, İlhami; Barut, Şener; Ural, Önur; Batırel, Ayşe; Mıstık, Reşit; Şi̇mşek, Funda; Asan, Ali; Ersöz, Gülden Munis; Türker, Nesrin Akbaş; Bilgin, Hüseyin; Kınıklı, Sami; Karakeçili, Faruk; Zararsız, Gökmen; Günal, Özgür; Akhan, Sıla Cetin; Tulek, N.; İnan, Dilara; Çaǧatay, Arif Atahan; Gürbüz, Yunus; Şener, Alper; Çelikbaş, Aysel Kocagül; Çetinkaya, Rıza Aytaç; Kadanalı, Ayten; Hakyemez, İsmail Necati; Kuruüzüm, Ziya; Özel, Selcan Arslan; Korkmaz, Pınar Yagiz; Tuna, Nazan; Saltoǧlu, Neşe; Tarakçı, Hüseyin; Uysal, Burcu; Karagöz, Ergenekon; Koçulu, Safiye; Ayaz, Celal; Güzel, Deniz Kamalak; Türkoğlu, Emine; Demir, Nazlım Aktuğ; Şimşek, Sümeyra; Kantürk, Arzu; Akça, Mustafa Özgür; Evik, Güliz; Örmen, Bahar Kopraman; Sili, Uluhan; Hatipoǧlu, Çiǧdem Ataman; Binay, Umut Devrim; Kılıç, Sırrı; Arslan, Kader; Yenilmez, Ercan; Çomoǧlu, Şenol; Koç, Meliha Meriç; Gökgöz, Altan; Dursun, Zehra Beştepe; Sümer, Şua; Heper, Yasemin; Yíldírmak, Taner T.; Öztürk, Sinan; Güğül, Tuğba Demirel; Yüce, Zeynep Türe
    Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r ± DSV ± RBV combination regimen in a real-world clinical practice. Materials and Methods: Data from HCV genotype 1 and 4 patients treated with OMV/PTV/r ± DSV ± RBV (n=862) in 34 centers across Turkey between April 1, 2017 and August 31, 2018 were recorded in a large national database. Demographic, clinical, and virologic data were analyzed. Results: The mean age of the patients was 55.63, and 430 patients (49.9%) were male. The majority had HCV genotype 1b infection (77.3%), and 66.2% were treatment-naïve. Non-cirrhosis was present at baseline in 789 patients (91.5%). SVR12 rate was 99.1% in all patients. Seven patients had virologic failure. No significant differences were observed in SVR12 according to HCV genotypes. HCV RNA was undetectable at treatment week 4 in 90.9%, at treatment week 8 in 98.5%, and at the end of treatment (EOT) in 98.9%. SVR12 ratio was significantly higher in the non-cirrhotic patients compared to that in the compensated cirrhotic patients. Rates of adverse events (AEs) in the patients was 59.7%. Conclusion: The present real-life data of Turkey for the OBV/PTV/r ± DSV ± RBV treatment of patients with HCV genotype 1b, 1a, or 4 infection from 862 patients demonstrated high efficacy and a safety profile. © Copyright 2020 by The Turkish Society of Gastroenterology